68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy

This project developed a a new type of nuclide Ga-68 labeled DTPA-HSA probe, and with the inherent advantages of this nuclear medicine department, it has promoted the formulation of the production filing standard of the drug, and obtained the 68Ga-HSA injection that can be used for preclinical research and meets the clinical standards. Clinical research on 68Ga-HSA PET/CT imaging was carried out to provide a basis for the diagnosis and treatment of PLE patients.

Inclusion criteria

• Patients with digestive system tumors;
• Presence of hypoproteinemia or clinical manifestations of hypoplasma protein;
• Serum albumin <30 g/L, AAT>80 ml/d;
• Measurable lesions in imaging;
• Predicted survival greater than 3 months;

Exclusion criteria

• Severe hepatic or renal dysfunction;
• Pregnant or nursing;
• Known allergy to the investigational drug or its excipients in study;
• Unable to comply with the PET/CT imaging procedures;
• Claustrophobia or other psychiatric disorders;
• Other conditions deemed unsuitable for participation in the trial;